INMB – inmune bio inc. - common stock (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

INMB

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

9/27

01:10 pm

inmb

Rating for INMB

Medium Report

Rating for INMB

Report

9/27

01:10 pm

inmb

Rating for INMB

Medium Report

Rating for INMB

Report

9/27

07:41 am

inmb

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.

Low Report

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.

Report

9/27

07:41 am

inmb

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.

Low Report

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.

Report

9/26

04:26 pm

inmb

INmune Bio initiated with bullish view at Raymond James

Low Report

INmune Bio initiated with bullish view at Raymond James

Report

9/26

04:26 pm

inmb

INmune Bio initiated with bullish view at Raymond James

Low Report

INmune Bio initiated with bullish view at Raymond James

Report

8/22

08:30 am

inmb

Rating for INMB

Medium Report

Rating for INMB

Report

8/22

08:30 am

inmb

Rating for INMB

Medium Report

Rating for INMB

Report

8/22

08:10 am

inmb

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock.

Medium Report

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock.

Report

8/22

08:10 am

inmb

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock.

Medium Report

INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock.

Report

8/21

04:15 pm

inmb

INmune Bio initiated with bullish view at Scotiabank

Medium Report

INmune Bio initiated with bullish view at Scotiabank

Report

8/21

04:15 pm

inmb

INmune Bio initiated with bullish view at Scotiabank

Medium Report

INmune Bio initiated with bullish view at Scotiabank

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.